XBiotech Shares Surge On FDA Emergency Use Authorization Of Convalescent Plasma

(RTTNews) - XBiotech Inc. (XBIT) announced the FDA issued an emergency use authorization for COVID-19 Convalescent Plasma as a COVID-19 treatment, opening the door for the company's antibody screening technology used to identify Convalescent Plasma. Under Collaboration, BioBridge Global will be using XBiotech's COVID-19 antibody test to identify the convalescent blood products.

XBiotech said the Agency's preliminary findings show that the use of convalescent plasma (or blood with natural anti-COVD-19 antibodies from patients that recovered from the infection) is safe and effective in treating COVID-19.

Shares of XBiotech were up 14% in pre-market trade on Monday.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More